Weekender: 5 questions facing gene therapy in 2021

Signup | Forward Weekender Jan.​ 9,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — L.E.K. Consulting Life Sciences: What To Expect in 2021 Join us for L.E.K.'s "Life Sciences: What To Expect in 2021" webinar, on Jan. 28 at Noon ET / 9 am PT. Register today.   5 questions facing gene therapy in 2021 Gene therapy developers will need to address a series of setbacks that have shaded optimism in the sector's fast growth. 5 FDA approval decisions to watch in the 1st quarter Bristol Myers and Bluebird are awaiting an FDA decision on their multiple myeloma cell therapy ide-cel, and could also soon get news on their lymphoma CAR-T drug liso-cel. How an all-or-nothing bet on 3 Bristol Myers drugs came undone With no decision from the FDA on approval of an experimental cancer cell therapy, an agreement by Bristol Myers to pay out more money as part of its Celgene acquisition fell apart.  Sponsored Content Iowa Economic Development Authority The roadmap to Iowa's bioscience revolution Discover how Iowa enhanced its bioscience industry with an emphasis on medical devices, biobased chemicals, precision agriculture, vaccines and immunotherapeutics. Download now. Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial Sarepta, though, may try to seek accelerated approval using Phase 2 data that's due imminently, along with results from another, smaller trial. AbbVie, Biogen lead pharma in new year's drug price hikes Average list price increases across the drug industry, however, appear lower than last year, according to one analysis.  Celgene's cell therapy spinout nets $292M from blank-check merger With additional financing, Celularity will have $372 million to back development of off-the-shelf treatments for cancer and autoimmune diseases.   BROUGHT TO YOU BY — Covance Analysis of Risk-Based Quality Management in Clinical Trials From reductions in early terminations to fewer critical findings from oversight monitoring visits, implementing a risk-based quality management approach to clinical trials via our award-winning Xcellerate technology platform can help you get your drugs and medical devices to market faster. Learn how.   From Our Library Infographic The Biologic's Path to Clinic Catalent Trendline Inside the Rapidly Changing World of Gene Therapy Industry Report The Future of Orphan Drugs Catalent Webinar - on demand Taking the First Step Toward a Critical Evolution of Pharma’s Commercial Model ZS Associates View all resources Best of What We're Reading STAT With success in vaccines, scientists turn mRNA on autoimmune disease Reuters Sanofi says could help produce competitors' COVID-19 shots Evaluate Vantage Astrazeneca shows megamergers were still possible in 2020 STAT Serial biotech entrepreneur John Hood targets deadly lung disease POLITICO Biden to phase out Operation Warp Speed co-leader Boston Business Journal Three months after launch, precision medicine startup Scorpion Therapeutics raises $162M Suggest a story we should read Upcoming Event Overcoming Barriers to Treatment Adherence With Flexible Patient Services Jan. 28, 2021 - Jan. 28, 2021 | Webinar 2pm ET Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of ​ , , ,​ . We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip